Today, Two Labs, an Envision Pharma Company and industry leader in pharma services, officially launched its Sunshine Transparency and Aggregate Spend service. This service offering is designed to help emerging pharmaceutical manufacturers streamline their aggregate spend activities, including reporting payments and transfers of value provided to healthcare professionals (HCPs) and healthcare organizations (HCOs).
A lot of work goes into getting a new pharma product across the finish line, especially if you’re an emerging manufacturer launching your first product. Every element of a launch strategy is important, but certain components outweigh others.
The FDA has several special designations or programs to facilitate the development of drugs treating
conditions with an unmet medical need. Certain designations can reduce FDA timelines for reviewing a New Drug Application (NDA) or Biologics License Application (BLA).
With only a few months left until the final DSCSA compliance deadline, our Director of Serialization, Michael Rowe, shared his thoughts in an Outsourced Pharma article on what companies should be doing now to make sure they’re ready.
